Other languages Johnson & Johnson Xetra

Equities

Market Closed - Xetra Other stock markets 16:35:46 03/07/2024 BST			After market 19:02:44
134.4 ^EUR	-1.50%		135.2	+0.60%

04:30pm	Johnson & Johnson's Rybrevant Approved by Health Canada to Treat Advanced Lung Cancer	MT
02:43pm	Johnson & Johnson Lung Cancer Drug Gets Health Canada Approval	DJ

Momentum Picks Q3/ 2024: 5 Aktien für den Sommer	04:20pm
Johnson & Johnson's Rybrevant Approved by Health Canada to Treat Advanced Lung Cancer	03:30pm
J&J : approbation complète pour Sirturo dans la tuberculose	11:07am
Momentum Picks T3 2024: 5 valores para el verano	07-02
Momentum Picks Q3 2024: vijf aandelen voor de zomer	07-02
J&J : résultats prometteurs dans le myélome multiple	07-02
Johnson & Johnson Says Interim Analysis of Blood Cancer Therapy Study Show Promise	07-02
Johnson & Johnson Announces Positive Results from Prespecified Second Interim Analysis of the Phase 3 CARTITUDE-4 Study Evaluating CARVYKTI	07-02
Momentum Picks Q3 2024: 5 azioni per l'estate	07-01
Momentum Picks T3 2024 : 5 actions pour l'été	07-01
En Direct des Marchés : Thales, Airbus, Sanofi, Stellantis, Atos, Valneva, Boeing...	07-01
Nouveau semestre, nouvel état d'esprit	07-01
Borsa di Italia: Un nuovo semestre, un nuovo umore	07-01
Bolsa de Madrid: Un nuevo semestre, un nuevo estado de ánimo	07-01
Johnson & Johnson Reports 'Positive' Results in Late-Stage Myasthenia Gravis Trial	06-28
J&J Unit's Rybrevant Combo Gets EU Approval	06-28
Johnson & Johnson Announces Positive Results from the Nipocalimab Phase 3 Vivacity-MG3 Study	06-28
Johnson & Johnson's Balversa Gets EU Panel Recommendation for Urothelial Carcinoma	06-28
Dealmakers optimistic on global M&A prospects despite sluggish growth	06-28
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	06-27

No results for this search

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 05:30 pm